Predictive value of cardiac magnetic resonance right ventricular longitudinal strain in patients with suspected myocarditis.
Cardiac magnetic resonance imaging
Feature tracking
Heart failure hospitalizations
Myocarditis
Right ventricle
Right ventricular global longitudinal strain
Journal
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
ISSN: 1532-429X
Titre abrégé: J Cardiovasc Magn Reson
Pays: England
ID NLM: 9815616
Informations de publication
Date de publication:
17 08 2023
17 08 2023
Historique:
received:
23
02
2023
accepted:
07
08
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
16
8
2023
Statut:
epublish
Résumé
Recent evidence underlined the importance of right (RV) involvement in suspected myocarditis. We aim to analyze the possible incremental prognostic value from RV global longitudinal strain (GLS) by CMR. Patients referred for CMR, meeting clinical criteria for suspected myocarditis and no other cardiomyopathy were enrolled in a dual-center register cohort study. Ejection fraction (EF), GLS and tissue characteristics were assessed in both ventricles to assess their association to first major adverse cardiovascular events (MACE) including hospitalization for heart failure (HF), ventricular tachycardia (VT), recurrent myocarditis and death. Among 659 patients (62.8% male; 48.1 ± 16.1 years), RV GLS was impaired (> - 15.4%) in 144 (21.9%) individuals, of whom 76 (58%), 108 (77.1%), 27 (18.8%) and 40 (32.8%) had impaired right ventricular ejection fraction (RVEF), impaired left ventricular ejection fraction (LVEF), RV late gadolinium enhancement (LGE) or RV edema, respectively. After a median observation time of 3.7 years, 45 (6.8%) patients were hospitalized for HF, 42 (6.4%) patients died, 33 (5%) developed VT and 16 (2.4%) had recurrent myocarditis. Impaired RV GLS was associated with MACE (HR = 1.07, 95% CI 1.04-1.10; p < 0.001), HF hospitalization (HR = 1.17, 95% CI 1.12-1.23; p < 0.001), and death (HR = 1.07, 95% CI 1.02-1.12; p = 0.004), but not with VT and recurrent myocarditis in univariate analysis. RV GLS lost its association with outcomes, when adjusted for RVEF, LVEF, LV GLS and LV LGE extent. RV strain is associated with MACE, HF hospitalization and death but has neither independent nor incremental prognostic value after adjustment for RV and LV function and tissue characteristics. Therefore, assessing RV GLS in the setting of myocarditis has only limited value.
Sections du résumé
BACKGROUND
Recent evidence underlined the importance of right (RV) involvement in suspected myocarditis. We aim to analyze the possible incremental prognostic value from RV global longitudinal strain (GLS) by CMR.
METHODS
Patients referred for CMR, meeting clinical criteria for suspected myocarditis and no other cardiomyopathy were enrolled in a dual-center register cohort study. Ejection fraction (EF), GLS and tissue characteristics were assessed in both ventricles to assess their association to first major adverse cardiovascular events (MACE) including hospitalization for heart failure (HF), ventricular tachycardia (VT), recurrent myocarditis and death.
RESULTS
Among 659 patients (62.8% male; 48.1 ± 16.1 years), RV GLS was impaired (> - 15.4%) in 144 (21.9%) individuals, of whom 76 (58%), 108 (77.1%), 27 (18.8%) and 40 (32.8%) had impaired right ventricular ejection fraction (RVEF), impaired left ventricular ejection fraction (LVEF), RV late gadolinium enhancement (LGE) or RV edema, respectively. After a median observation time of 3.7 years, 45 (6.8%) patients were hospitalized for HF, 42 (6.4%) patients died, 33 (5%) developed VT and 16 (2.4%) had recurrent myocarditis. Impaired RV GLS was associated with MACE (HR = 1.07, 95% CI 1.04-1.10; p < 0.001), HF hospitalization (HR = 1.17, 95% CI 1.12-1.23; p < 0.001), and death (HR = 1.07, 95% CI 1.02-1.12; p = 0.004), but not with VT and recurrent myocarditis in univariate analysis. RV GLS lost its association with outcomes, when adjusted for RVEF, LVEF, LV GLS and LV LGE extent.
CONCLUSION
RV strain is associated with MACE, HF hospitalization and death but has neither independent nor incremental prognostic value after adjustment for RV and LV function and tissue characteristics. Therefore, assessing RV GLS in the setting of myocarditis has only limited value.
Identifiants
pubmed: 37587516
doi: 10.1186/s12968-023-00957-6
pii: 10.1186/s12968-023-00957-6
pmc: PMC10433613
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Banques de données
ClinicalTrials.gov
['NCT04774549', 'NCT03470571']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
49Informations de copyright
© 2023. Society for Cardiovascular Magnetic Resonance.
Références
JACC Cardiovasc Imaging. 2018 Oct;11(10):1419-1429
pubmed: 29361479
Front Cardiovasc Med. 2021 Oct 12;8:743849
pubmed: 34712713
Eur J Radiol. 2017 Apr;89:97-105
pubmed: 28267556
JACC Cardiovasc Imaging. 2020 Feb;13(2 Pt 1):494-507
pubmed: 31202742
Int J Cardiol. 2018 Nov 15;271:359-365
pubmed: 30045820
Rofo. 2018 Aug;190(8):722-732
pubmed: 30045397
J Am Heart Assoc. 2020 Aug 18;9(16):e015351
pubmed: 32787653
Circulation. 2008 Aug 5;118(6):639-48
pubmed: 18645053
Front Cardiovasc Med. 2021 Nov 30;8:765274
pubmed: 34917664
JACC Cardiovasc Imaging. 2020 Sep;13(9):1891-1901
pubmed: 32682718
J Cardiovasc Magn Reson. 2020 Dec 14;22(1):87
pubmed: 33308262
J Cardiovasc Magn Reson. 2019 Feb 28;21(1):14
pubmed: 30813942
J Am Coll Cardiol. 2017 Oct 17;70(16):1964-1976
pubmed: 29025553
Heart. 2021 Jul 12;107(15):1233-1239
pubmed: 33139324
Int J Cardiovasc Imaging. 2019 Jun;35(6):1067-1078
pubmed: 30756221
N Engl J Med. 2009 Apr 9;360(15):1526-38
pubmed: 19357408
JACC Cardiovasc Imaging. 2022 Jul;15(7):1325-1338
pubmed: 35592889
Circulation. 2010 Aug 31;122(9):900-9
pubmed: 20713901
Circ Arrhythm Electrophysiol. 2017 Jan;10(1):
pubmed: 28087564
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
Int J Cardiol. 2018 Feb 1;252:220-223
pubmed: 29133275
Heart. 2014 Nov;100(21):1673-80
pubmed: 24860005
Circulation. 2017 Feb 21;135(8):717-719
pubmed: 28223323
JACC Cardiovasc Imaging. 2023 Jan;16(1):28-41
pubmed: 36599567
Eur Radiol. 2021 Jun;31(6):3962-3972
pubmed: 33277669
J Cardiovasc Med (Hagerstown). 2007 Oct;8(10):807-14
pubmed: 17885519
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Int J Cardiol. 2017 Mar 1;230:364-370
pubmed: 28040278
J Cardiovasc Comput Tomogr. 2022 Jul-Aug;16(4):309-318
pubmed: 35148996
Eur Radiol. 2022 May;32(5):3436-3446
pubmed: 34932165
Circulation. 2002 Jan 29;105(4):539-42
pubmed: 11815441
J Cardiovasc Magn Reson. 2017 Sep 1;19(1):66
pubmed: 28863780
J Am Coll Cardiol. 2012 May 1;59(18):1604-15
pubmed: 22365425
Eur Radiol. 2011 Oct;21(10):2111-20
pubmed: 21614615
Data Brief. 2017 Nov 12;16:244-249
pubmed: 29226213
Eur Radiol. 2019 Jul;29(7):3686-3695
pubmed: 31041566
Echocardiography. 2015 Feb;32(2):257-63
pubmed: 24975738
J Cardiovasc Magn Reson. 2020 Jul 23;22(1):51
pubmed: 32698811
Circ Cardiovasc Imaging. 2021 Jan;14(1):e011492
pubmed: 33441003
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
JAMA. 2013 Mar 6;309(9):896-908
pubmed: 23462786
J Am Coll Cardiol. 2018 Nov 6;72(19):2360-2379
pubmed: 30384893
Int J Cardiovasc Imaging. 2010 Jan;26(1):57-64
pubmed: 19757150